Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Growth in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 107,600 shares, a growth of 139.6% from the January 31st total of 44,900 shares. Based on an average daily volume of 387,900 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.7% of the company’s stock are short sold.

Protagenic Therapeutics Price Performance

Protagenic Therapeutics stock traded up $0.02 during mid-day trading on Friday, reaching $0.31. 580,508 shares of the company traded hands, compared to its average volume of 195,305. Protagenic Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $1.87. The firm’s fifty day moving average is $0.40 and its two-hundred day moving average is $0.55. The company has a market capitalization of $2.21 million, a price-to-earnings ratio of -0.24 and a beta of 0.25.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.